Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) EBIT (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBIT for 7 consecutive years, with -$17.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 82.56% to -$17.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$383.7 million, a 7.67% increase, with the full-year FY2025 number at -$383.7 million, up 7.67% from a year prior.
  • EBIT was -$17.4 million for Q4 2025 at Beam Therapeutics, up from -$126.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $132.9 million in Q4 2023 to a low of -$200.4 million in Q1 2021.
  • A 5-year average of -$85.3 million and a median of -$99.5 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 606.66% in 2021, then skyrocketed 249.3% in 2023.
  • Beam Therapeutics' EBIT stood at -$63.5 million in 2021, then tumbled by 40.17% to -$89.0 million in 2022, then surged by 249.3% to $132.9 million in 2023, then crashed by 175.3% to -$100.0 million in 2024, then soared by 82.56% to -$17.4 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's EBIT are -$17.4 million (Q4 2025), -$126.8 million (Q3 2025), and -$120.2 million (Q2 2025).